The Hospice Recertification Flexibility Act extends the ability for hospice providers to use telehealth for patient recertifications (verifying ongoing eligibility for hospice care) until December 31, 2027, instead of ending in March 2025. It specifies that telehealth recertifications will not apply in certain cases starting January 1, 2026, such as when patients are in areas with a hospice enrollment moratorium or when providers are under enhanced oversight. The bill also requires hospice claims for telehealth recertifications on or after January 1, 2026, to include a specific modifier or code indicating the telehealth encounter. This change directly affects hospice providers and their patients by modifying how remote eligibility checks are processed under Medicare.
HRES 166 is a non-binding House resolution expressing U.S. support for the Iranian people's desire for a democratic, secular, and nonnuclear republic. It condemns the Iranian regime's terrorism, regional proxy wars, internal suppression of ethnic and religious minorities, and human rights abuses - including executions and repression of women-led protests. The resolution calls for holding the regime accountable through sanctions, supports the Ten-Point Plan for Iran’s democratic transition, and urges protection for Iranian political refugees in Albania. It does not create new laws but affirms U.S. policy alignment with Iranian protesters' demands.
This bill creates a streamlined process for out-of-state healthcare providers to enroll in Medicaid or CHIP (Children's Health Insurance Program) in a state. It directly affects children under 21 enrolled in these programs and healthcare providers located in other states who already meet low fraud risk standards. The key provision requires states to adopt a simplified enrollment process using only basic provider information (like name and National Provider Identifier), granting eligible providers a 5-year enrollment period without repeated screening. This reduces administrative barriers for providers serving out-of-state children under 21 who qualify for Medicaid or CHIP coverage.
This bill awards a Congressional Gold Medal to the 761st Tank Battalion (known as the "Black Panthers"), the first predominantly Black armored unit in World War II's European Theater. It recognizes their combat service from 1944-1946, including key roles in the Battle of the Bulge and breaking the Siegfried Line, despite facing racial prejudice during and after the war. The medal will be displayed at the National Museum of African American History and Culture, with bronze duplicates available for sale to cover costs. The bill commemorates the battalion's 130,000 enemy casualties inflicted, 50% casualty rate, and their 1978 Presidential Unit Citation. It does not create new laws or affect current policies.
HR 1614 would amend Section 1834(m)(4)(E) of the Social Security Act to expand which healthcare providers can offer telehealth services to Medicare beneficiaries. The bill directly affects Medicare patients and current healthcare providers (like nurse practitioners, physician assistants, and clinical psychologists) who are currently excluded from providing telehealth under Medicare. The key change is modifying the legal language to explicitly include these additional providers in the list of eligible telehealth furnishers. This policy change would allow more Medicare beneficiaries to access telehealth services from a broader range of qualified healthcare professionals.
This bill extends duty-free access for Haitian apparel exports to the U.S. until September 30, 2035, under the Caribbean Basin Economic Recovery Act. It increases the minimum percentage of eligible apparel that qualifies for duty-free treatment to 60% or more and adjusts import limits to 1.25% of the U.S. apparel import market. The bill also restores eligibility for specific apparel items that lost duty-free status due to past tariff schedule changes. These changes directly benefit Haitian apparel manufacturers and U.S. importers of Haitian-made clothing by maintaining market access.
This bill changes rules for prescribing certain medications used to treat substance use disorders. It allows healthcare providers to use telehealth for the initial patient evaluation instead of requiring an in-person visit, but only for drugs approved by the FDA for addiction treatment (schedules III-V). The telehealth must meet specific standards, including real-time audio/video communication. This affects doctors and other practitioners who prescribe these medications for substance use disorders.
HR 1633, the Workforce Reentry Act, creates federal grants to help formerly incarcerated individuals (ex-offenders) find and maintain jobs after release. It provides two funding mechanisms: pay-for-performance contracts (using at least 30% of funds) where grantees earn payments based on meeting specific job placement and earnings targets, and competitive grants for skills training, job placement, and mentoring services. Grantees must coordinate with existing workforce systems, use evidence-based programs, and cannot directly fund housing or treatment (only coordinate with other providers). The bill requires annual reporting on participant outcomes like program completion and employment rates, plus a 5-year independent evaluation to assess recidivism reduction and job success.
This bill amends Medicare rules to allow nurse practitioners and physician assistants to certify diabetic shoe coverage for Medicare beneficiaries with diabetes, expanding the current requirement that only physicians could provide this documentation. It directly affects Medicare patients needing specialized footwear due to diabetes and healthcare providers like NPs and PAs who would now be authorized to meet the certification requirement. The key change modifies Section 1861(s)(12) of the Social Security Act to insert "nurse practitioner, or physician assistant" in all relevant sections of the documentation rules. This update simplifies access to covered diabetic shoes by broadening which healthcare professionals can issue the necessary certification.
SJRES 24 is a joint resolution that would block an Environmental Protection Agency (EPA) rule setting new standards for reducing harmful air pollutants from rubber tire manufacturing facilities. If passed, the resolution would prevent the rule - published in the Federal Register on November 29, 2024 - from taking effect, meaning tire manufacturers would not have to comply with the new requirements. The bill directly affects the rubber tire manufacturing industry by removing a specific regulatory obligation. This resolution uses a congressional disapproval process under federal law to stop the EPA rule without creating new regulations.
SRES 95 is a non-binding Senate resolution designating February 23-March 1, 2025, as "National Fentanyl Awareness Week" to highlight the dangers of fentanyl in the U.S. It does not create new laws but encourages public awareness about fentanyl's extreme potency (50x stronger than heroin) and its role in overdose deaths, citing CDC data showing fentanyl-related poisonings as the leading cause of death for U.S. adults aged 18-45. The resolution urges individuals to use only prescribed medications, seek treatment for substance use disorder, and supports law enforcement efforts combating fentanyl trafficking. It directly affects the general public by promoting education and prevention during the designated awareness period.
This bill modifies requirements for pediatric drug studies, particularly for drugs treating rare diseases (orphan drugs). It requires the FDA to issue a noncompliance letter and allow 45 days for response before imposing penalties, and creates an automatic FDA waiver list for diseases where pediatric studies are impractical. Drug sponsors developing orphan drugs for rare conditions will benefit from clearer pathways, as the bill specifies when pediatric studies aren't required unless they offer meaningful therapeutic benefit. The FDA must also report on penalties for noncompliance and update its waiver lists, aiming to streamline development while improving pediatric data for rare diseases.
